RT Journal Article
SR Electronic
T1 A unique SARS-CoV-2 spike protein P681H strain detected in Israel
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.25.21253908
DO 10.1101/2021.03.25.21253908
A1 Zuckerman, Neta S.
A1 Fleishon, Shay
A1 Bucris, Efrat
A1 Bar-Ilan, Dana
A1 Linial, Michal
A1 Bar-Or, Itay
A1 Indenbaum, Victoria
A1 Weil, Merav
A1 Israel National Consortium for SARS-CoV-2 sequencing
A1 Mendelson, Ella
A1 Mandelboim, Michal
A1 Mor, Orna
YR 2021
UL http://medrxiv.org/content/early/2021/03/28/2021.03.25.21253908.abstract
AB Routine detection, surveillance and reporting of SARS-CoV-2 novel variants is important, as these threaten to hinder vaccination efforts. Herein we report a local novel strain that includes a non-synonymous mutation in the spike (S) protein - P681H and additional synonymous mutations. The P681H Israeli strain has not been associated with higher infection rates and was neutralized by sera from vaccinated individuals in comparable levels to the B.1.1.7 strain and a non-P681H strain from Israel.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional IRB committee at Sheba Medical Center, Israel. Approval #7045-20-SMC https://rnd.sheba.co.il/research_authority Chairman of the IRB committee: Prof. Dror HaratsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data has been deposited to GISAID.